转移性非小细胞肺癌中与生存相关的纵向循环肿瘤DNA模型
基于随机3期IMpower150研究中466例非小细胞肺癌患者5个时间点的循环肿瘤DNA(ctDNA),用机器学习联合建模预测总生存期。治疗至第3周期第1天的ctDNA可对疾病稳定和部分缓解患者进行风险分层;外部OAK研究验证了高危患者识别;模拟提示早期ctDNA检测预测试验结局优于早期影像学。
要点
- 治疗至第3周期第1天的ctDNA动态可对疾病稳定患者进行风险分层,高危与低-中危中位OS为7.1个月 vs 22.3个月。
- 部分缓解患者中高危与低-中危中位OS为8.8个月 vs 28.6个月。
- 外部OAK研究验证该模型可识别高危患者,总生存HR为3.73。
核心结论
- 治疗期间测量ctDNA动态可改善患者风险分层,并可能允许在临床试验中早期区分竞争性疗法。
研究设计与样本
- 基于随机3期IMpower150研究,比较化疗-免疫检查点抑制剂联合方案,在466例非小细胞肺癌患者中评估5个时间点的ctDNA,并使用机器学习联合建模多个ctDNA指标以预测总生存期。
- 外部验证队列来自随机3期OAK研究,比较免疫检查点抑制剂与化疗在非小细胞肺癌中的疗效。
主要发现
- 模拟临床试验场景提示,早期ctDNA检测在预测试验结局方面优于早期影像学检查。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small or nonrandomized. We assessed ctDNA across 5 time points in 466 non-small-cell lung cancer (NSCLC) patients from the randomized phase 3 IMpower150 study comparing chemotherapy-immune checkpoint inhibitor (chemo-ICI) combinations and used machine learning to jointly model multiple ctDNA metrics to predict overall survival (OS). ctDNA assessments through cycle 3 day 1 of treatment enabled risk stratification of patients with stable disease (hazard ratio (HR) = 3.2 (2.0-5.3), P < 0.001; median 7.1 versus 22.3 months for high- versus low-intermediate risk) and with partial response (HR = 3.3 (1.7-6.4), P < 0.001; median 8.8 versus 28.6 months). The model also identified high-risk patients in an external validation cohort from the randomized phase 3 OAK study of ICI versus chemo in NSCLC (OS HR = 3.73 (1.83-7.60), P = 0.00012). Simulations of clinical trial scenarios employing our ctDNA model suggested that early ctDNA testing outperforms early radiographic imaging for predicting trial outcomes. Overall, measuring ctDNA dynamics during treatment can improve patient risk stratification and may allow early differentiation between competing therapies during clinical trials.
引用
- Assaf ZJF, Zou W, Fine AD, et al. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med. 2023. PMID: 36928816. doi:10.1038/s41591-023-02226-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。